Saurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.
Saurabh Dahiya, MBBS, associate professor of Medicine, director, Cellular Immunotherapy in Leukemia and Lymphoma, University of Maryland School of Medicine, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel (axi-cel; Yescarta) in large B-cell lymphoma (LBCL).
A real-world analysis examined patients who received treatment with axi-cel therapy.
At a median follow-up of 32.3 months, axi-cel elicited a median overall survival (OS) that was not reached, Dahiya says. Moreover, the 3-year OS rate was 52%, compared with 47% in ZUMA-1, Dahiya adds. Real-world data demonstrated a median progression free survival (PFS) of 9 months, vs 5.9 months in ZUMA-1, and the 3-year PFS in the follow up was 41%, compared with 40% in ZUMA-1, Dahiya explains.
It is important to note these data were observed in a real-world population, compared with results from a clinical trial, Dahiya concludes.